GRP and neoplasm: Korkmaz et al. [23] (Korkmaz, Koksal et al. 2018) suggested a panel of three serum tumor biomarkers, CYFRA21-1, HE4, and progastrin-releasing peptide (ProGRP) that might contribute to discriminating lung cancer from BLD.